V160-001-002: A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults

Project: Other project

StatusFinished
Effective start/end date6/27/146/26/18

Funding

  • Merck Sharp & Dohme Corporation: $282,978.38